Patient P-02549
Synthetic patientMETA-24 · Day 179 · 55–64 · M · baseline S14Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Improving
GI state
Favorable
Inflammatory state
Deteriorating
Nutritional resilience
Favorable
Discontinuation risk
29%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 32 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 32.
Primary contributors, last 14 days
- Inflammatory activity+8
- Toxicity-5
- GI instability+4
- Treatment adherence+2
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable73 min
improving · +4.9 vs previous 14 d
Sleep duration
Wearable6.5 h
stable · -0.2 vs previous 14 d
Energy level
Daily log6.2/10
improving · +0.4 vs previous 14 d
Steps
Wearable7,197
improving · +592 vs previous 14 d
GI burden
Companion21.5/100
improving · -10.2 vs previous 14 d
Adherence
Companion84 %
stable · -1.4 vs previous 14 d
Sleep quality
Wearable36.5/100
stable · -0.0 vs previous 14 d
Glucose, CGM daily mean
CGM126 mg/dL
stable · -2.4 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 63 from the failing basin, 47 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -3.8 next day on high-intake days · n 21
- More simple carbsGI -2 next day on high-intake days · n 15
Would not help
- BR-03 Behavioural Recommendationonly 22% improved among 9 similar
- Keep alcohol lowGI +3.2 next day on high-intake days · n 15
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-3.8supporter · 95%
- Alcohol+3.2detractor · 74%
- Ultra-processed food-2.2no signal · 52%
- Simple carbohydrates-2supporter · 59%
- Caffeine+1.9no signal · 41%
- Insoluble fibre+1.2no signal · 34%
- Dietary fat load-1.1no signal · 24%
- Histamine load+0.7no signal · 21%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
DNA
Fictional pharmacogenomic panel
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 4.3 · butyrate capacity 68/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 40 ms
- Sleep
- 6.2 h
- Steps
- 7,180
- Resting HR
- 64 bpm
Daily log: GI score 22, nutritional resilience 68, adherence 84.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02564 | 48% | S15 | BR-03 | improved | 32 |
| P-02016 | 46% | S20 | DT-01 | improved | 27 |
| P-02331 | 40% | S14 | BR-03 | improved | 34 |
| P-02033 | 34% | S06 | GI-04 | improved | 51 |
| P-02391 | 34% | S19 | HY-01 | improved | 53 |
| P-02455 | 34% | S09 | DT-01 | improved | 50 |
| P-02494 | 34% | S09 | GI-04 | improved | 47 |
| P-02223 | 33% | S20 | HY-01 | improved | 49 |
| P-02339 | 33% | S03 | DT-01 | improved | 50 |
| P-02479 | 33% | S13 | DT-01 | improved | 48 |
| P-02484 | 33% | S15 | GI-04 | improved | 49 |
| P-02031 | 32% | S12 | AD-05 | improved | 47 |